Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

LLM 2021 | Cold and warm autoimmune hemolytic anemia

Catherine Broome • 13 Oct 2021

LLM 2021

Anemias

Catherine Broome, MD, Lombardi Cancer Center, Washington, DC, gives an update on autoimmune hemolytic anemias. Warm autoimmune hemolytic anemia accounts for around 80% of all autoimmune hemolytic anemias, and it’s mediated by an IgG autoantibody. While cold autoimmune hemolytic anemia is less common, accounting for about 15-18% of cases, and it’s mediated by an IgM autoantibody that subsequently, after binding to the antigen on the surface of the red blood cell, activates the classical pathway of complement, which is responsible for hemolysis. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Disclosures

Sanofi, Argenx, Rigel, Alexion, Annexon, Cellphire

Unmet needs in the treatment and management of cold agglutinin disease

Catherine Broome • 18 Dec 2023

Targeting the complement cascade in autoimmune hemolytic anemias

Catherine Broome • 18 Dec 2023

Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA

Catherine Broome • 18 Dec 2023

Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP

Catherine Broome • 18 Dec 2023

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia

Antonio Risitano • 16 Apr 2024

Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency

Hanny Al-Samkari • 9 Dec 2023

SATISFY: mitapivat in patients with erythrocyte membranopathies

Kevin Kuo • 10 Dec 2023